Redilanz 2,5 mg.5,0 mg.10,0 mg. 15,0 mg FC tablets
PDF Leaflet Revision Date: 14 December 2017
Clinical Summary
Quick overview from the medicine insert
Indication
Management of psychotic disorders and acute mania.
Dosage (summary)
Initial dose 5-10 mg/day, target 10 mg/day; range 5-20 mg/day.
Onset of Action / Duration
Onset: 5-8 hours, Duration: Not specified
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Safety during pregnancy and lactation not established.
Key Drug Interactions
- CNS depressants
- Levodopa
- Antihypertensives
- QT prolonging agents
Contraindications
- Hypersensitivity to olanzapine
- Narrow-angle glaucoma
- Children under 18
- Dementia-related psychosis
Common side effects
- Somnolence
- Weight gain
- Orthostatic hypotension
- Hyperglycaemia
Counselling Points
- Monitor for hyperglycaemia
- Avoid alcohol
- Gradual dose tapering recommended
- Caution with driving
Serious warnings
- Neuroleptic malignant syndrome
- Tardive dyskinesia
- Hyperprolactinaemia
- Withdrawal symptoms
Important Disclaimer
The Redilanz 2,5 mg.5,0 mg.10,0 mg. 15,0 mg FC tablets professional information leaflet below is the property of Dr Reddy’S Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
